肝细胞癌术后辅助治疗的现状与展望
Current status and prospects of postoperative adjuvant therapy for hepatocellular carcinoma
曾永毅 1傅俊 1林孔英 1郭洛彬1
作者信息
- 1. 福建医科大学孟超肝胆医院肝胆外科,福州 350001
- 折叠
摘要
肝细胞癌肝切除术后高复发转移率严重影响患者预后.探索肝细胞癌术后辅助治疗的适应证和有效方案,以降低术后复发率并改善长期生存具有重要临床意义.传统的局部治疗手段,包括经导管动脉化疗栓塞、肝动脉灌注化疗、放射治疗等,在术后辅助治疗继续发挥重要作用.近年来,随着分子靶向药物、免疫检查点抑制剂等新兴系统治疗药物应用,不仅改变了术后辅助治疗格局,治疗选择也变得更加复杂和多样化.笔者结合目前辅助治疗的最新进展,探讨肝癌术后辅助治疗策略以及面临的挑战.
Abstract
The high recurrence and metastasis rate of hepatocellular carcinoma(HCC)in patients after hepatectomy significantly impact the prognosis.Exploring effective strategies and indi-cations of postoperative adjuvant therapy for HCC is of great clinical significance in reducing postop-erative recurrence rate and improving long-term survival.Traditional local treatment modalities,including transcatheter arterial chemoembolization,hepatic artery infusion chemotherapy,and radiotherapy,continue to play a crucial role in postoperative adjuvant therapy.Recently,the emer-gence of novel systemic therapy agents,including molecular targeted drugs and immune checkpoint inhibitors,has transformed the landscape of postoperative adjuvant therapy,making the selection of adjuvant therapy more intricate and diverse.The author combines the latest progress in adjuvant therapy to explore the strategies and challenges of postoperative adjuvant therapy for HCC.
关键词
肝肿瘤/手术切除/局部治疗/靶向治疗/免疫治疗Key words
Liver neoplasms/Surgical resection/Local therapy/Targeted therapy/Immunotherapy引用本文复制引用
基金项目
国家自然科学基金(62275050)
福建省科技创新联合资金项目(2019Y9108)
福建省卫健委中青年科研重大项目(2021ZQNZD013)
出版年
2024
NETL
NSTL
万方数据